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Abstract
Cyclooxygenase 2 (COX-2) inhibitors have been shown to enhance tumor’s response to radiation in several animal
models. The strong association of COX-2 and angiogenesis suggests that the tumor vasculature may be involved
in this process. The current study investigated whether treatment with the COX-2 inhibitor E-6087 could influence
response to local radiation in orthotopically growing murine gliomas and aimed to analyze the involvement of the
tumor vasculature. GL261 glioma cells were injected into the cerebrum of C57bl/6 mice. From day 7 after tumor
cell injection, mice were treated with COX-2 inhibitor at 50 mg/kg i.p. every third day. Radiation consisted of three
fractions of 2 Gy given daily from day 9 to day 11. Mice were killed at day 21. The COX-2 inhibitor significantly
enhanced the response to radiation, reducing mean volume to 32% of tumors treated with radiation only. The
combination treatment neither increased apoptosis of tumor cells or stromal cells nor affected tumor microvascu-
lar density. In vitro, E-6087 and its active metabolite did not affect clonogenic survival of GL261 cells or human
umbilical vein endothelial cell after radiation. In vivo, however, there was a nonsignificant increase in Angiopoietin
(Ang)-1 and Tie-2 mRNA levels and a decrease of Ang-2 mRNA levels after combination treatment. These changes
coincided with a significant increase in α-smooth muscle actin–positive pericyte coverage of tumor vessels. In
conclusion, the antitumor effect of radiation on murine intracranial glioma growth is augmented by combining with
COX-2 inhibition. Our findings suggest an involvement of the tumor vasculature in the observed effects.
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Introduction
The growth of solid tumors depends on the formation of new vessels
from preexisting ones, or angiogenesis. In angiogenesis research, glio-
mas have received special attention because of their high vascular
density. Cyclooxygenase 2 (COX-2), an inducible prostaglandin syn-
thetase, is strongly associated with tumor angiogenesis [1]. It is over-
expressed in gliomas and in other tumors, and its expression is
correlated with vascular density and prognosis [2,3]. Inhibition of
COX-2 resulted in a reduction of angiogenesis [4] and in a reduction
of glioma growth [5].
COX-inhibitors have been shown to exert a synergistic antitumor
effect in combination with radiation treatment in several tumors
in vivo [6–10]. Some controversy exists about the molecular and cel-
lular basis for this synergy. The ability of COX-2 inhibitors to sup-
press neovascularization suggests that mechanisms related to tumor
vascular function may be involved in the radiosensitizing effects of
these drugs [11].
The aim of our research, therefore, was to analyze the effects of
the combination of a COX-2 inhibitor with radiotherapy on gliomas
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in cerebro and to investigate to what extent the tumor vasculature is
involved in the therapeutic response. We used a model that uses
orthotopically implanted syngeneic GL261 glioma cells in C57bl/6
mice. In this model, invasive growth and neovascularization have
been extensively described [12,13].
We here demonstrate a reduced outgrowth of intracranial glioma
caused by the systemic addition of a COX-2 inhibitor to local frac-
tionated radiation and find indications for the involvement of the
tumor vasculature in the observed antitumor effects.
Materials and Methods
COX-1 and COX-2 Inhibitory Effects
The effect of E-6087 (see Figure 1 for chemical structure) on
COX-1 and COX-2 enzymatic activity was assessed according to a
modification of the method described by Takeguchi and Sih [14].
In vivo, E-6087 is metabolized into another active compound,
E-6132 (Figure 1), which was analyzed for its effect on COX-1 and
-2 activity in the same way. For comparison, the effect of celecoxib was
assessed in parallel.
In vivo, prostaglandin E2 (PGE2) production inhibition was deter-
mined in a rat inflammatory exudate (COX-2) and gastric mucosa
(COX-1) model, as previously described [15]. The PGE2 generation
was determined by enzyme immunoassay using an immunoassay de-
tection kit (Cayman Chemical Co., Ann Arbor, MI; Catalog no. 5140)
according to the manufacturer’s instructions.
E-6087 and E-6132 have been synthesized at the Chemistry De-
partment of Laboratorios Esteve (Barcelona, Spain).
Cells
Human umbilical vein endothelial cells (HUVECs) were ob-
tained from the Endothelial Cell Facility UMCG (Groningen, the
Netherlands). Cells were isolated and cultured as previously de-
scribed [16].
GL261 murine glioma cells, kindly provided by Dr. U Herrlinger
(Hertie Institute for Clinical Brain Research, Tubingen, Germany),
were cultured in tissue culture flasks at 37°C under 5% CO2–95%
air. The GL261 culture medium consisted of Dulbecco’s modified
Eagle’s medium supplemented with 10% FCS, 2 mM L-glutamine,
and 1% gentamicin (Biowittaker, Verviers, Belgium). All experiments
were performed with confluent GL261 monolayers, except for the
clonogenic survival assays, in which confluency status was as de-
scribed below.
Animals
Immunocompetent male C57bl/6 mice were purchased from
Harlan (Horst, the Netherlands). Animals were maintained on
mouse chow and acidified tap water ad libitum in a temperature-
controlled chamber at 24°C with a 12-hour light/dark cycle. The
mice were monitored daily for behavior and every other day for
body weight. All experiments were approved by the local ethics
committee on animal research and were performed in accordance
with the Dutch Code of Practice for animal experiments in oncologi-
cal research.
Animal Experimental Procedures
GL261 murine glioma cells, which are syngeneic to C57bl/6 mice,
were orthotopically implanted. This model was chosen for its known
invasive properties [13] and its well-documented induction of neo-
angiogenesis [12]. Implantation of GL261 cells into the brains of
C57bl/6 mice was performed under anesthesia. All procedures re-
quiring anesthesia were performed using ketamine (75 mg/kg) and
medetomidine (1 mg/kg) i.p. Animals recovered from anesthesia
after i.m. injection with Antisedan (0.6 mg/kg). Additionally, for
analgesia during tumor cell implantations, Rimadyl (5 mg/kg) was
administered s.c.
Three microliters of tumor cell suspension (100,000 cells/μl) was
stereotactically inoculated in the left striate nucleus using a 10-μl
SGE syringe (SGE Scientific, Melbourne, Australia).
On day 7 after tumor cell inoculation, mice were randomly as-
signed to treatment groups. Mice were i.p. injected with COX-2 in-
hibitor E-6087 (50 mg/kg) suspended in 5% gum arabic (15 mg/ml)
every third day, until the end of the experiment (day 21). Control
mice received injections with vehicle only. Local radiation in three
fractions was started at day 9, for 3 consecutive days, one fraction of
2 Gy/day (1.8 Gy/min) to a total of 6 Gy. Mice were radiated using a
MGC 41 X-ray machine (Yxlon International, Hamburg, Germany;
200 kV, 10 mA). The animals were anesthetized and positioned under
a leaden shield (thickness >3 mm). Radiation was performed through a
1 × 0.8-cm rectangular hole in the shield that was positioned over the left
cerebral hemisphere. Tumor-bearing control mice were sham-radiated.
On day 21, mice were anesthetized, and the brains were removed
under perfusion with sterile 0.9% NaCl. The brains were snap frozen
in isopentane and stored at −80°C.
Tumor Volume Measurements
For tumor volume measurements, mouse brains were mounted on
a cryostat (CM 1900; Leica, Wetzlar, Germany), and the cutting of
5-μm cryosections was started at the rostral end. Tumor volumes
Figure 1. Chemical structures of E-6087 and its metabolite E-6132.
E-6087 (a crystalline solid with a molecular weight of 405.35) is
an inhibitor of cyclo-oxygenase with preferential effects on COX-2.
In vivo, it is metabolized into the even more potent COX-2 inhibitor
E-6132, with plasma concentrations of the metabolite in rats being
lower than those of the parental compound. Pharmacokinetics
studies of E-6087 in rats and dogs [29] showed peak plasma con-
centrations 2 to 7 hours after oral administration. Elimination t1/2
was 15 to 34 hours with a plasma clearance of 0.1 to 0.22 L/h per
kilogram. These parameters varied with species and gender.
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were calculated from surface area measurements of every 20th tissue
section of the tumor.
Clonogenic Survival Assay
Human umbilical vein endothelial cells (first passage) and GL261
(up to passage 40) were plated in 25-cm2 gelatin-coated culture flasks
in increasing densities (ranging from 100 to 100,000 cells per flask).
Twenty-four hours after plating, cells were radiated with graded
doses (0, 3, 5, or 10 Gy) with a Cs-137 γ-ray machine (dose rate:
0.765 Gy/min). Two hours before radiation, cells were incubated
with either E-6087 or E-6132 in a concentration of 10 μM or vehicle
only in EC medium. Feeder cells consisted of HUVEC or GL261
cells radiated with a lethal dose of 100 Gy (100,000 cells per flask,
added before radiation; dose rate: 2.226 Gy/min). Half of the medium
was refreshed for the first time after 8 days. After 14 days, cultures
were gently washed with phosphate-buffered saline, and colonies were
stained with crystal violet 1% (Sigma, St. Louis, MO) in ethanol
30%–formaldehyde 3% in demineralized water. Colonies containing
more than 50 cells were counted. A minimum of two independent
experiments were performed per experimental setup.
Immunohistochemistry
Cryostat sections were immunohistochemically analyzed using
standard protocols. The primary antibodies used recognized CD31
(Catalog no. 55027; BD Biosciences-PharMingen, San Diego, CA), cas-
pase 3a (Catalog no. 557035; BD Biosciences-PharMingen), COX2
(Catalog no. ab21704; Abcam, Cambridge, UK), CD45 (Catalog
no. 550539; BD Biosciences-PharMingen).
Similarly, fluorescence double staining was performed using standard
protocols. The primary antibodies used recognized CD31, desmin
(Catalog no. ab152001; Abcam), and α-smooth muscle actin (αSMA;
Cy3-labeled, Catalog no. C6198; Sigma-Aldrich).
Determination of Tumor Microvascular Density
Microvascular density (MVD) was scored using the Chalkley point
overlap morphometric technique, which allows for rapid analysis
with a relatively low interobserver variability [17]. This method
has been described in detail [18]. In brief, three vascular hot spots
were identified per tumor. A 25-point Chalkley eyepiece graticule
(Graticules Ltd, Edenbridge, Kent, UK) was used to score each
hot spot at a magnification of ×200. The graticule was oriented to
permit the maximum number of points to hit the immunohisto-
chemically visualized microvessels. This procedure was performed
in duplicate. The MVD per tumor was obtained by calculating the
mean of these three hot spots. Results were confirmed by the inde-
pendent analysis of a second observer.
Analysis of Pericyte Coverage of Tumor Vessels
Cryosections were double stained for CD31 and αSMA or desmin.
Per tumor, six or more random high-power fields were analyzed on a
fluorescence microscope (Quantimed 600S; Leica Camera, Solms,
Germany) equipped with a 40× objective lens (Leica PL Fluotar).
Using the appropriate filters, images were captured with the Leica
QWin 3 software. All vessels within the high-power field were ana-
lyzed. A minimum of 30 vessels per tumor were scored. The percent-
age of vessels that showed any perivascular staining for αSMA or
desmin was scored. Results were confirmed by the independent analy-
sis of a second observer.
Gene Expression Analysis by Real-time Reverse
Transcription–Polymerase Chain Reaction
Total RNA was isolated with Absolutely RNA Micropep Kit
(Stratagene, Amsterdam, the Netherlands) according to the protocol
of the manufacturer.
RNA was analyzed qualitatively by gel electrophoresis and quanti-
tatively using Nanodrop (Nanodrop Technologies, Rockland, DE).
One microgram of total cellular RNA was subsequently used for
the synthesis of first-strand cDNA with SuperScript III RNase H
minus reverse transcriptase (Invitrogen, Breda, the Netherlands) in a
20-μl final volume containing 250 ng of random hexamers (Promega,
Benelux, Leiden, the Netherlands) and 40 U of RNase OUT inhibitor
(Invitrogen). After the RT reaction, 1 μl of cDNA was used for each
PCR. Exons overlapping primers and minor groove binder probes used
for real-time reverse transcription–polymerase chain reaction (RT-
PCR) were purchased as Assay-on-Demand from Applied Biosystems
(Nieuwekerk a/d IJssel, the Netherlands). As a control, water was
analyzed to exclude unspecific signals arising from impurities and con-
sistently showed no amplification signals. TaqMan PCR was per-
formed as previously described [16].
Statistical Analysis
Statistical significance of differences was tested with GraphPad
Prism 3 (GraphPad Software, La Jolla, CA) using the one-way analy-
sis of variance assuming normal distribution of the data. The differ-
ences were considered significant at P < .05.
Results
E-6087 and E-6132 Are Potent and Selective Inhibitors
of COX-2 In Vitro and In Vivo
Both E-6087 and E-6132 were potent inhibitors of the COX-2
enzymatic activity. E-6087 was more than 100-fold selective for
COX-2 versus COX-1 [IC50 (μM): COX-1, 334 (95% confidence
interval (CI), 226-442); and COX-2, 2.93 (95% CI, 2.03-3.83)].
In the case of its main metabolite, the selectivity for COX-2 over
COX-1 was >250-fold [IC50 (μM): COX-1, 134 (95% CI, 10-259);
and COX-2, 0.5 (95% CI, 0.11-0.88)]. For comparison, the selectiv-
ity of celecoxib was >300-fold [IC50 (μM): COX-1, 90.2 (95% CI,
73.5-106.7); and COX-2, 0.28 (95% CI, 0.15-0.41)]. E-6087 and
E-6132 potently inhibited the production of PGE2 in rat carrageenan-
induced inflammatory exudates, with per os (p.o.) ED50 for E-6087
of 7.38 mg/kg (SEM 1.3) and for E-6132 1.8 mg/kg (SEM 0.2).
The ED50 for celecoxib was 2.85 mg/kg (SEM 0.61). In contrast,
no significant inhibition of PGE2 production was observed in gastric
mucosa samples even when the compounds were administered at the
highest dose tested (40 mg/kg, p.o. for E-6087 and E-6132; 20 mg/kg
for celecoxib).
Combination of COX-2 Inhibition and Radiation
Therapy Resulted in a Significant Additive Reduction
in Glioma Outgrowth
We initiated intracerebral tumors in 28 mice and randomly as-
signed mice to one of four study groups (n = 7). One mouse died
before the end of the experiment. Its death was unrelated to tumor
growth, administration of COX-2 inhibitor, or radiation treatment.
Two more mice (one from the COX-2 inhibitor group and one from
the combination group) did not grow any identifiable tumor and
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were excluded from the study. As such a take rate 93% was established.
After exclusion of these three mice, three groups of six mice each and
one group of seven mice (radiation group) remained. Mean tumor
volume of the untreated group was the largest of all four groups
(52.7 mm3, SD 11.2), differing significantly from the radiation group
(P < .001) with mean tumor volume of 22.4 mm3 (SD 12.1; Figure 2).
The mean tumor volume of the group treated with the combination
of COX-2 inhibitor and fractionated radiation was the lowest of all
groups: 7.1 mm3 (SD 4.6). Besides a difference with the untreated
group (P < .001), this volume was significantly smaller than the mean
tumor volume of the group treated with radiation only (P < .05). The
variance in the group treated with COX-2 inhibitor only (mean tumor
volume, 25.7 mm3 (SD 27.9)) was such that no significant difference
was found with the other groups (combination vs COX-2 inhibitor
alone; P = .14). Representative microscopic images of tumors from
the four treatment groups are shown in Figure 3. They illustrate the
dramatic differences between the groups at the end of the experiment,
varying from dense compact tumors in the control group to disinte-
grated tumors in the combination group.
Tumor Cells Are Not Targeted by the COX-2 Inhibitor
To investigate whether the tumor cells could present as a possible
target of COX-2 inhibition, we analyzed COX-2 mRNA expression
in GL261 cells in vitro and in vivo by real-time RT-PCR. In vitro, no
COX-2 mRNA was detected in the GL261 cell line. In vivo, COX-2
gene expression was detectable in the tumors, which may be attrib-
uted to tumor stroma–associated cells, including endothelial cells and
tumor-infiltrating leukocytes. Radiation did not affect the levels of
COX-2 mRNA in vitro and in vivo (data not shown). However, im-
munohistochemistry showed more cells in the glioma tumor tissue
staining positive for COX-2 in both the radiation-only group and
in the combination treatment group. The distribution of COX-2–
positive cells was consistent with the distribution of leukocytes as
stained with CD45 (data not shown).
Because a COX-2–negative state of the tumor cells does not exclude
COX-2–independent inhibiting effects on tumor cells [19], we next
analyzed tumor cell apoptosis. Active caspase 3 (caspase 3a) staining
was virtually absent in the untreated group and in the mice treated
with COX-2 inhibitor only. Variable amounts of caspase 3a–positive
cells were detected in the radiation group and in the mice treated with
COX-2 inhibitor plus radiation. The distribution of the apoptotic
cells, however, colocalized with the distribution of the infiltrating leu-
kocytes as identified by CD45 immunohistochemical staining, sug-
gesting that the therapeutic strategies used here induced cell death
in the host-derived tumor-infiltrating leukocytes.
In the absence of induction of apoptosis, a change in clonogenic
survival may explain alteration of the tumor’s response to radiation.
In the clonogenic survival assay, however, no significant effects of
E-6087 on survival after radiation could be detected. To exclude the
possibility of an actual clonogenic cell death–inducing effect by the
active metabolite E-6132, which is formed in vivo from E-6087, we
repeated the experiment with this metabolite. Although E-6132 did
reduce clonogenic survival in tumor cells, the extent of reduction
was constant regardless of radiation dosage and was statistically not sig-
nificant (data not shown).
Tumor Vasculature as a Possible Target for COX-2
Inhibition Plus Radiation Therapy
As described above, increased apoptosis was observed in the tumor-
infiltrating leukocytes after combination therapy. An immunofluores-
cence double staining procedure was not able to colocalize tumor
endothelial cells, as identified by CD31 (PECAM-1) staining and cas-
pase 3a positivity (data not shown).
If the additional antitumor effect of the combination treatment
were to be related to the destruction of tumor vessels during the
treatment period, this vascular effect may be represented by a change
in MVD. The Chalkley point grid analyses of CD31-stained tumor
vessels, however, demonstrated that the MVD was similar in all four
groups. Because a vascular effect cannot be unambiguously excluded
based on MVD data, we analyzed in vitro whether COX-2 inhibition
affected radiation-induced clonogenic cell survival of HUVEC. Yet,
both E-6087 and its active metabolite E-6132 neither significantly
attenuated nor enhanced clonogenic cell survival in these cells (data
not shown).
Combination Therapy Leads to Changes in the Tumor
Vasculature Which Identifies the Vasculature as Target
for Therapy
The absence of an apoptosis- or clonogenic death–inducing ef-
fect on endothelial cells and the absence of a change in MVD do
not a priori exclude the occurrence of a change in angiogenic poten-
tial as a result of combination treatment. We therefore studied the
effects of the combination treatment on the expression levels of vas-
cular endothelial growth factor (VEGF), the Ang/Tie-2 system, and
other angiogenesis-related genes by real-time RT-PCR analysis (n = 3).
As an indication of the biologic activity of E-6087, we observed an
increase in COX-2 mRNA in animals treated with COX-2 inhibitor
Figure 2. Antitumor effects of the COX-2 inhibitor E-6087 and local
radiation in fractions on intracranial murine glioma growth. Oneweek
after tumor cell inoculation, mice were left untreated, treated with
COX-2 inhibitor, treated with radiation, or treated with a combination
of COX-2 inhibitor and radiation. (*) Combination therapy (mean
tumor volume, 7.1 mm3) significantly reduced tumor outgrowth
compared with radiation-only (mean tumor volume, 22.4 mm3;
P < .05) and compared with nontreated tumors (mean tumor vol-
ume, 52.7 mm3; P < .001). Mean tumor volume of mice treated
with COX-2 inhibitor was 25.7 mm3. The mean volume per group
is presented, n = 6, except for the radiation group for which
n = 7, ± SEM.
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and radiation (mRNA vs GAPDH of radiation vs combination treat-
ment: 1.23 × 10−5 vs 3.88 × 10−5, P < .05; Figure 4). Using Western
blot, a similar inducing effect, paralleled by a decrease in the COX-2
product PGE2, was demonstrated by Kang et al. [10] after the incu-
bation of U87MG cells with celecoxib. Both results are indicative of
a positive feedback loop induced by the inhibition of COX-2 activity.
The increase in COX-2 mRNA in our study coincided with non-
significant increases in VEGFR-1, hypoxia-inducible factor 1α, and
Tie-2. The mRNA levels of integrin αv showed a decrease in animals
treated with COX-2 inhibition and radiation compared with the non-
treated group (mRNA vs GAPDH 15.4 × 10−3 vs 10.7 × 10−3, respec-
tively, P < .05). However, the mRNA levels of integrin αv did not show
a significant difference between the radiation and the combination
group. The mRNA levels of VEGF-A, VEGFR-2, VE-cadherin, in-
tegrin β3, and CD31 were similar in all four treatment groups (data
not shown). The group treated with COX-2 inhibition and radiation
showed a statistically nonsignificant increase in the expression of Ang-1
(one-way analysis of variance, P = .055), whereas Ang-2 showed a non-
significant decrease of gene expression (P = .199; Figure 5). In line with
this, there was a nonsignificant increase in the Ang-1/Ang-2 ratio as a
result of COX-2 inhibition and radiation (P = .075).
Shifts in the gene expression of the angiopoietin system can be
expected to be found in case of changes in vessel maturation. Al-
though the changes in gene expression of this system did not reach
significance in this study, these changes prompted us to analyze an
additional parameter of the maturation status of the tumor vascula-
ture, which is the extent of coverage of the vasculature with pericytes.
Staining for the pericyte markers αSMA and desmin showed a sig-
nificant increase in αSMA-positive pericyte coverage of tumor vessels
(Figure 5), corroborating the trends seen in mRNA analysis. Interest-
ingly, staining for desmin was similar in all four groups.
Discussion
In this study, we showed that the administration of the COX-2
inhibitor E-6087 in addition to radiation treatment increases the
antitumor effect of the treatment on intracranial murine glioma
growth compared with radiation only. The added effect of combina-
tion treatment was strong, reducing mean tumor volumes by almost
Figure 3. Combination therapy for COX-2 inhibition and radiation reduced tumor cell density and led to an apparent disintegration of
the tumor. Representative cryosections of tumors harvested at the end of the treatment period and stained with hematoxylin. Original
magnification, ×100. (A) Nontreated tumor. (B) COX-2 inhibitor treatment (50 mg/kg every third day starting at day 7 after inoculation of
tumor cells). (C) Fractionated radiation (three fractions of 2 Gy for 3 consecutive days starting at day 9). (D) Combination therapy for
COX-2 inhibition and radiation. The tumors treated with a combination of COX-2 inhibition and radiation showed a clear decrease in
tumor cell density with apparent cellular and stromal defects not seen to the same extent in other treatment groups.
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70% compared with radiation treatment. The treatment did not af-
fect tumor and endothelial cell proliferation and apoptosis. However,
(neo)vascularization-related gene expression, but especially pericyte
coverage of tumor vessels, may indicate that normalization of the
tumor vasculature accompanied the reduced tumor growth.
The results presented here corroborate those of previous studies,
which showed an enhancement of tumor radioresponse by COX in-
hibitors in vivo in several tumor types [6,7,20,21]. Kang et al. [10]
recently confirmed the effect of combination treatment in an intra-
cranial murine glioma model using U87 xenografts. Kang et al.
showed a direct effect of this treatment on tumor cells in vitro. The
absence of such an effect in our study may be explained by the fact
that the GL261 cells used in our model do not express COX-2 in vitro.
However, the growth inhibition of tumor cells by COX-2 inhibitors
can occur in a COX-2–independent way [22,23]. Nonetheless, no
effect of the combination treatment on the tumor cells was seen either
in vitro or in vivo.
If the sensitization of radiation by COX-2 inhibition is not brought
about by directly affecting the tumor cells then the tumor stroma must
be involved.
Inhibition of angiogenesis may be of importance in the enhance-
ment of radioresponsiveness induced by COX-2 inhibitors [24,25].
Masferrer et al. [1] demonstrated the antitumor effect of celecoxib in
tumor models in which only the tumor endothelial cells were express-
ing COX-2. Kang et al. [10] demonstrated a reduction of MVD and
changes in the gene expression levels of VEGF and the angiopoietin
system after the combination treatment of radiation and celecoxib.
We were not able to detect enhanced apoptosis or reduced clonogenic
survival in endothelial cells after treatment with COX-2 inhibitors and
radiation. Moreover, the MVD did not change as a response to treat-
ment. The changes we found in the expression levels of the Ang/Tie-
2 system, with an increase in the expression of Tie-2 and Ang-1, and
a concomitant decrease in the expression of Ang-2, were all statistically
nonsignificant. Nonetheless, this is in complete opposition with the de-
creased protein levels of VEGF and Ang-1, concomitant with an in-
creased expression of Ang-2 in U87MG cells, found after radiation
and incubation with celecoxib [10]. Several differences in study design
may underlie these contradictory outcomes. First, Kang et al. measured
the levels of the angiopoietin proteins in glioma cells in vitro. In vivo,
however, the production of Ang-1 and Ang-2 relies on a number of dif-
ferent cell types, with the tumor cells or pericytes often accounting
for Ang-1, and the endothelial cells for Ang-2 production. Second,
in our study, we used real-time RT-PCR to measure gene expression,
which neglects possible posttranscriptional regulation of two angiopoie-
tin proteins. The results of the Ang/Tie-2 gene expression analysis
prompted us to analyze tumor vessel maturation and study whether
Figure 4. COX-2 inhibition induced an up-regulation of COX-2 gene
expression. Gene expression was analyzed with real-time RT-PCR.
CT values were related to GAPDH gene expression. Gene expres-
sion is presented as fold increase in mRNA content normalized to
the non treated control group. (*) The mean mRNA level of the
mice treated with the combination of COX-2 inhibition and radia-
tion was significantly increased compared to the control and radia-
tion group, P < .05, n = 3, ± SEM.
Figure 5. Changes in gene expression of Ang-1 and Ang-2 and peri-
cyte coverage of tumor vessels are indicative of vessel normalization.
(A) Ang-1 and Ang-2 gene expression in the different treatment con-
ditions versus untreated controls. mRNA content was compared
with GAPDH, n = 3, ± SEM. (B) αSMA-positive pericyte coverage
of tumor vessels determined by CD31/αSMA double fluorescent im-
munostaining and subsequent quantification. (*) In response to treat-
ment with a combination of E-6087 and radiation there is an increase
in αSMA-positive pericyte coverage of tumor vessels compared to all
other treatment groups, P < .05, n = 3, ± SEM.
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vessel normalization had occurred. Vessel normalization is a process that
counteracts changes in vascular behavior induced by the angiogenic pro-
cess. It is hypothesized that tumor angiogenesis can be initiated only after
a switch in the balance of Ang-1 and -2 in favor of the latter. It is the aim
of vessel normalization therapy to reverse this switch. The clinical rele-
vance and feasibility of vessel normalization have been illustrated in a
clinical [26] and a preclinical setting [27]. Vessel normalization is associ-
ated with a recovery of pericyte coverage of the tumor vessels [28], a fea-
ture that was also seen in our current study. Because therapy in ourmodel
started relatively early, the suppressive effects of the treatment leading to
vessel normalization possibly inhibited the ability of the tumor to induce
an effective angiogenic switch and thereby inhibited tumor outgrowth.
In summary, we showed that COX-2 inhibition effectively inhibited
GL261 intracranial glioma outgrowth when combined with radiation
therapy. The changes in the tumor vasculature suggest a role for vessel
normalization in the effects brought about. Further studies will be ini-
tiated to determine the molecular and cellular basis for the observed
effects of the combination therapy. The strong effects warrant further
studies on the feasibility of adding COX-2 inhibitor treatment to daily
clinical practice in the treatment of high-grade glioma.
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